The US FDA has approved Papzimeos for adults suffering from recurrent respiratory papillomatosis. Precigen received the approval after trials showed positive results. Fifty-one percent of patients experienced complete response, needing no surgeries for a year. Papzimeos is a nonreplicating immunotherapy targeting the root cause of RRP. The treatment involves four subcutaneous injections over twelve weeks.